Cell and Gene Commercialization

31. Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation 9/18/2025

    As the cell therapy space evolves beyond T cells, allogeneic natural killer (NK) cell therapies are emerging as a scalable and accessible approach in cancer immunotherapy. Cell & Gene's Chief Editor, Erin Harris, welcomed experts Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics, and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, for a detailed discussion exploring how their teams are advancing the field through distinct yet complementary strategies. The dynamic discussion highlighted the scientific innovation, technological differentiation, and patient-centered vision driving the next generation of allogeneic NK cell therapies, and why now is the critical moment to deepen research and exploration into novel NK platforms.

32. 2024 Cell And Gene Therapy Report: Advancing The Future Of Medicine 9/2/2025

    Cell and gene therapies offer hope for cures, but face significant barriers to broader patient access. Find out how industry leaders are working to overcome these challenges.

33. Navigating Commercial Logistics: Key Considerations For Emerging CGT Manufacturers 8/27/2025

    A successful cell and gene therapy launch requires a logistics strategy that keeps patients at the center, plans for disruptions, and prepares for future growth and global expansion.

34. Precigen Secures FDA Approval For PAPZIMEOS And Redefines RRP Treatment 8/27/2025

    Precigen has received FDA approval for PAPZIMEOS, the first therapy for recurrent respiratory papillomatosis, marking a major advance in patient care.

35. Discover The Path To Oncology Success 8/22/2025

    The oncology landscape is brimming with innovative therapies and new treatment approaches. Successful commercialization requires a well-orchestrated strategy to bring these complex products to market.

36. Don't Let Distribution Derail Your CGT Launch 8/7/2025

    Overcoming distribution challenges is critical for the success of cell and gene therapies. Learn how to build a flexible, robust strategy to optimize patient access.

37. The Building Blocks Of A Robust Analytical Assay 8/1/2025

    Analytical assays aren't just important for quality control. Regulators expect them. These tips will help if you're just starting to build your analytical package.

38. Rethinking Partnerships In Cell & Gene Therapy 7/30/2025

    Discover how a unique partnership model helps cell and gene therapy developers accelerate progress, reduce risk, and bring transformative therapies to market faster.

39. Navigating The Complexities Of NK Cell Therapy Development 7/30/2025

    Deloitte's Amit Agarwal and Ashraf Husain share expert insights on how NK cell therapy developers can overcome manufacturing, supply chain, and commercialization challenges to successfully scale these promising therapies.

40. Optimizing Commercial Distribution As You Prepare To Launch Your CGT 7/29/2025

    An effective commercial distribution strategy is crucial for new cell and gene therapies, helping manufacturers navigate challenges and ensure patient access.